Drug intelligence / Profile preview

SmarT

Development stage: Unknown
Lead developer: Comprehensive Cancer Centre of Drum Tower Hospital, Nanjing University

Overview

SmarT is an investigational drug being evaluated in a clinical trial for the first-line treatment of locally advanced unresectable or metastatic, HER2 negative gastric / gastroesophageal junction adenocarcinoma (GEJ). It is administered as part of a combination regimen that includes a PD-1 antibody, chemotherapy (oxaliplatin and S-1), and low-dose radiotherapy. The specific mechanism of action for SmarT itself is not detailed in the provided context, but it is intended to be used in conjunction with established cancer therapies.

Other names: Smart

Beyond the preview

Go deeper on SmarT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SmarT.

Explore the full profile